Galecto Inc. Merges with San Diego-based PharmAkea, Inc.
January 9, 2020
Copenhagen-headquartered Galecto Inc. (a Novo Seeds portfolio company) has merged with San Diego-based PharmAkea, Inc. The combined clinical-stage company will retain the Galecto name, be incorporated in the United States, and combine complementary pipelines in fibrosis and oncology to accelerate development of small-molecule and galectin-targeting therapeutics.
- Buyers
- Galecto, Inc.
- Targets
- PharmAkea, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Pharmacosmos Acquires G1 Therapeutics
August 7, 2024
Biotechnology
Pharmacosmos A/S, through its U.S. affiliate Pharmacosmos Therapeutics Inc., agreed to acquire all outstanding shares of G1 Therapeutics, Inc. for $7.15 per share in cash, implying an approximate equity value of $405 million. The deal brings G1's FDA-approved oncology product COSELA into Pharmacosmos' commercial portfolio to accelerate patient access and expand Pharmacosmos' presence in oncology and supportive care.
-
Bayer AG Acquires Asklepios BioPharmaceutical (AskBio)
October 26, 2020
Biotechnology
Bayer AG agreed to acquire U.S.-headquartered Asklepios BioPharmaceutical (AskBio), adding AskBio's AAV-based gene therapy platform, IP and CDMO manufacturing capabilities to Bayer’s emerging cell and gene therapy unit. Bayer will pay $2.0 billion upfront plus up to $2.0 billion in potential milestone payments; existing minority shareholders TPG Capital and Vida Ventures supported the transaction.
-
Takeda Acquires GammaDelta Therapeutics
October 27, 2021
Biotechnology
Takeda Pharmaceutical Company Limited has exercised its option to acquire GammaDelta Therapeutics Limited, obtaining the company's allogeneic Vδ1 γδ T cell therapy platforms and early-stage cell therapy programs. The acquisition, stemming from a multi-year collaboration begun in 2017, is for a pre-negotiated upfront payment plus potential milestone payments and is expected to close in Q1 of Takeda's fiscal 2022, subject to antitrust review.
-
Sorrento Therapeutics Acquires ACEA Therapeutics
June 1, 2021
Biotechnology
Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.
-
PharmaForceIQ Acquires Aktana
January 9, 2026
Cloud & SaaS
PharmaForceIQ has acquired Aktana in an asset acquisition to integrate Aktana's AI-driven field Next-Best-Action platform into PharmaForceIQ's digital orchestration offering. The deal is intended to create an end-to-end 'optichannel-in-a-box' commercial engagement solution for life sciences, deepen PharmaForceIQ's U.S. footprint and expand reach across LATAM, APAC and EMEA; Canaccord Genuity acted as sole financial advisor.
-
PCI Pharma Services Acquires Ajinomoto Althea
May 1, 2025
Healthcare Services
PCI Pharma Services has completed the acquisition of Ajinomoto Althea, Inc., a US-based sterile fill-finish CDMO previously owned by Ajinomoto Co., Inc. The deal expands PCI’s US sterile manufacturing footprint in San Diego—adding prefilled syringe and cartridge aseptic capabilities, lyophilization and high-potent vial filling (including ADC support)—and is part of a multi-year, roughly $1 billion investment strategy to broaden advanced drug delivery and fill‑finish capacity.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.